These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 6331296

  • 21. Susceptibility of "enterobacteria" to aminoglycoside antibiotics: comparisons with tetracyclines, polymyxins, chloramphenicol, and spectinomycin.
    Finland M, Garner C, Wilcox C, Sabath LD.
    J Infect Dis; 1976 Aug; 134 Suppl():S57-74. PubMed ID: 184213
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Antibacterial synergism of polymyxin B nonapeptide and hydrophobic antibiotics in experimental gram-negative infections in mice.
    Ofek I, Cohen S, Rahmani R, Kabha K, Tamarkin D, Herzig Y, Rubinstein E.
    Antimicrob Agents Chemother; 1994 Feb; 38(2):374-7. PubMed ID: 8192470
    [Abstract] [Full Text] [Related]

  • 24. Genotypic characterization and in vitro activities of tigecycline and polymyxin B for members of the Enterobacteriaceae with decreased susceptibility to carbapenems.
    Zhang R, Cai JC, Zhou HW, Nasu M, Chen GX.
    J Med Microbiol; 2011 Dec; 60(Pt 12):1813-1819. PubMed ID: 21835972
    [Abstract] [Full Text] [Related]

  • 25. Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.
    Vaara M.
    Molecules; 2019 Jan 11; 24(2):. PubMed ID: 30641878
    [Abstract] [Full Text] [Related]

  • 26. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Jan 11; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 27. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.
    Sader HS, Rhomberg PR, Farrell DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2015 Dec 11; 83(4):379-81. PubMed ID: 26415906
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Resistance to beta-lactam antibiotics and aminoglycosides in gram negative bacteria. 1. Molecular and genetic characterization of R-factors (author's transl)].
    Schmid B, Kayser FH.
    Zentralbl Bakteriol Orig A; 1976 Apr 11; 234(3):371-83. PubMed ID: 779353
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Antimicrobial activity of dactimicin in vitro compared with that of dibekacin, netilmicin, sisomicin and micronomicin.
    Inouye S, Hara T, Matsuhashi Y, Kitasato I.
    Drugs Exp Clin Res; 1989 Apr 11; 15(10):455-63. PubMed ID: 2632214
    [Abstract] [Full Text] [Related]

  • 34. The occurrence of the trehalose fermenting, tetracycline and polymyxin resistant phenotype among the Enterobacteriaceae.
    Siboni K.
    Acta Pathol Microbiol Scand B; 1980 Aug 11; 88(4):185-8. PubMed ID: 6251697
    [Abstract] [Full Text] [Related]

  • 35. Outer Membrane Interaction Kinetics of New Polymyxin B Analogs in Gram-Negative Bacilli.
    Akhoundsadegh N, Belanger CR, Hancock REW.
    Antimicrob Agents Chemother; 2019 Oct 11; 63(10):. PubMed ID: 31332075
    [Abstract] [Full Text] [Related]

  • 36. [Susceptibility of gram-negative bacterial isolates to six beta-lactam and two aminoglycoside antibiotics at our university hospital].
    Tanabe T, Kobayashi T, Yoshida S, Mizuguchi Y.
    J UOEH; 1988 Sep 01; 10(3):297-303. PubMed ID: 3175388
    [Abstract] [Full Text] [Related]

  • 37. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
    Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Møller N, He H, Poudyal A, Li J, Nation RL, Vaara T.
    Antimicrob Agents Chemother; 2010 Aug 01; 54(8):3341-6. PubMed ID: 20479195
    [Abstract] [Full Text] [Related]

  • 38. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria].
    Suzuki Y, Nishinari C, Endo H, Hiramatsu N, Akiyama K, Koyama T.
    Jpn J Antibiot; 2003 Aug 01; 56(4):309-35. PubMed ID: 14567255
    [Abstract] [Full Text] [Related]

  • 39. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS, Hsueh PR, Lee WS, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Lam C, Chen RJ.
    Int J Antimicrob Agents; 2013 May 01; 41(5):457-62. PubMed ID: 23507415
    [Abstract] [Full Text] [Related]

  • 40. The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.
    Tyrrell JM, Aboklaish AF, Walsh TR, Vaara T, Vaara M.
    Peptides; 2019 Feb 01; 112():149-153. PubMed ID: 30586602
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.